Literature DB >> 14661053

Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.

Stuart S Hobbs1, Elizabeth M Cameron, Robert P Hammer, Ann T D Le, Richard M Gallo, Erika N Blommel, Stephanie L Coffing, Han Chang, David J Riese.   

Abstract

The neuregulins (NRGs) are members of the epidermal growth factor (EGF) family of peptide growth factors. These hormones are agonists for the ErbB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ErbB1), ErbB2/Neu/HER2, ErbB3/HER3, and ErbB4/HER4. We recently observed that the EGF family hormone NRG2beta is a potent agonist for ErbB4. In contrast, NRG2alpha, a splicing isoform of the same gene that encodes NRG2beta, is a poor ErbB4 agonist. We hypothesized that carboxyl-terminal residues of NRG2beta are critical for stimulation of ErbB4 tyrosine phosphorylation and coupling to downstream signaling events. Here, we demonstrate that the substitution of a lysine residue for Phe45 in NRG2beta results in reduced ligand potency. We also demonstrate that substitution of a phenylalanine for Lys45 in NRG2alpha results in increased ligand potency. Finally, analyses of the gain-of-function NRG2alpha Chg5 mutant demonstrate that Gln43, Met47, Asn49, and Phe50 regulate ligand efficacy. Thus, these data indicate that carboxyl-terminal residues of NRG2beta are critical for activation of ErbB4 signaling. Moreover, these NRG2alpha and NRG2beta mutants reveal new insights into models for ligand-induced ErbB family receptor tyrosine phosphorylation and coupling to downstream signaling events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14661053     DOI: 10.1038/sj.onc.1207250

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

2.  Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  Medchemcomm       Date:  2011-01-01       Impact factor: 3.597

Review 3.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

Review 4.  EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Authors:  Kristy J Wilson; Christopher Mill; Sydney Lambert; Jennifer Buchman; Timothy R Wilson; Victor Hernandez-Gordillo; Richard M Gallo; Laura M C Ades; Jeffrey Settleman; David J Riese
Journal:  Growth Factors       Date:  2012-01-20       Impact factor: 2.511

5.  TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells.

Authors:  Stuart S Hobbs; Jeremy A Goettel; Dongchun Liang; Fang Yan; Karen L Edelblum; Mark R Frey; Matthew T Mullane; D Brent Polk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-12       Impact factor: 4.052

6.  The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Authors:  Kristy J Wilson; Christopher P Mill; Richard M Gallo; Elizabeth M Cameron; Henry VanBrocklin; Jeffrey Settleman; David J Riese
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

7.  A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2010-12

8.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

9.  Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.

Authors:  Seetharama Satyanarayanajois; Stephanie Villalba; Liu Jianchao; Go Mei Lin
Journal:  Chem Biol Drug Des       Date:  2009-09       Impact factor: 2.817

Review 10.  Functional selectivity of EGF family peptide growth factors: implications for cancer.

Authors:  Kristy J Wilson; Jennifer L Gilmore; John Foley; Mark A Lemmon; David J Riese
Journal:  Pharmacol Ther       Date:  2008-12-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.